The poor prognosis of this BC subtype was significantly improved with the advent of monoclonal antibodies (mAb) targeting HER2, namely trastuzumab and pertuzumab, and small molecules like tyrosine kinase inhibitors (TKI), such as lapatinib, tucatinib and neratinib. This evidence concerns the gene ERBB2 and breast cancer.